Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
, Zentrum für Innere Medizin
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 9, 2025, Nr. 4, e70114DOI (Open Access)
-
AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myelomaIn: Scientific Reports, Jg. 15, 2025, Nr. 1, 26455DOI (Open Access)
-
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation : A multicenter real-world analysisIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 9, 2025, Nr. 8, e70192DOI (Open Access)
-
Germline Single-Nucleotide Polymorphism GFI1-36N Causes Alterations in Mitochondrial Metabolism and Leads to Increased ROS-Mediated DNA Damage in a Murine Model of Human Acute Myeloid LeukemiaIn: Biomedicines, Jg. 13, 2025, Nr. 1, 107DOI (Open Access)
-
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma : An international multicenter studyIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 9, 2025, Nr. 1, e70070DOI (Open Access)
-
Impact of Acute Myeloid Leukemia Cells on the Metabolic Function of Bone Marrow Mesenchymal Stem CellsIn: International Journal of Molecular Sciences (IJMS), Jg. 26, 2025, Nr. 17, 8301DOI (Open Access)
-
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapyIn: Blood Cancer Journal, Jg. 14, 2024, Nr. 1, 214DOI (Open Access)
-
Multiple myeloma in the young : Insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sampleIn: Haematologica / The Hematology Journal, Jg. 109, 2024, Nr. 11, S. 3795 – 3799DOI (Open Access)
-
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple MyelomaIn: Cancers, Jg. 15, 2023, Nr. 8, 2373DOI (Open Access)
-
Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCsIn: Frontiers in Cell and Developmental Biology, Jg. 11, 2023, 866847DOI (Open Access)
-
Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cellsIn: British Journal of Haematology, Jg. 202, 2023, Nr. 5, S. 1033 – 1048DOI (Open Access)
-
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapyIn: Blood, Jg. 142, 2023, Nr. 25, S. 2175 – 2191DOI (Open Access)
-
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7) : Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialIn: The Lancet Haematology, Jg. 9, 2022, Nr. 11, S. e810 – e821
-
Curcumin as an epigenetic therapeutic agent in myelodysplastic syndromes (Mds)In: International Journal of Molecular Sciences (IJMS), Jg. 23, 2022, Nr. 1, 411DOI (Open Access)
-
Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cellsIn: British Journal of Haematology, Jg. 196, 2022, Nr. 4, S. 995 – 1006DOI (Open Access)
-
GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemiaIn: Leukemia, Jg. 36, 2022, Nr. 9, S. 2196 – 2207DOI (Open Access)
-
High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid LeukemiaIn: Cancers, Jg. 14, 2022, Nr. 3, 486DOI, Online Volltext (Open Access)
-
Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibitionIn: Frontiers in Oncology, Jg. 12, 2022, 903691DOI (Open Access)
-
Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in miceIn: Leukemia, Jg. 33, 2019, Nr. 1, S. 110 – 121DOI, Online Volltext (Open Access)
-
GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1.In: Nature Communications, Jg. 9, 2018, S. 1418DOI (Open Access)
-
GFI1 is required for RUNX1/ETO positive acute myeloid leukemiaIn: Haematologica / The Hematology Journal, Jg. 103, 2018, Nr. 9, S. e395 – e399DOI (Open Access)
-
Gfi1b : A key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndromeIn: Haematologica / The Hematology Journal, Jg. 103, 2018, Nr. 4, S. 614 – 625DOI (Open Access)
-
Enforced GFI1 expression impedes human and murine leukemic cell growth.In: Scientific Reports, Jg. 7, 2017, S. 15720DOI (Open Access)
-
GFI1B-A novel oncosuppressor which restricts number of leukemic stem stellsIn: Haematologica / The Hematology Journal, Jg. 102, 2017, Nr. Suppl. 2, S. 204 – 204
-
Growth factor independence 1 (GFI !) regulates the AML supporting function of mesenchymal stromal cellsIn: Haematologica / The Hematology Journal, Jg. 102, 2017, Nr. Suppl. 2, S. 459 – 459
-
Myelodysplastic syndromes and bone loss in mice and menIn: Leukemia, Jg. 31, 2017, Nr. 4, S. 1003 – 1007
-
A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2AIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 101, 2016, Nr. 3, S. 1016 – 1022DOI (Open Access)
-
Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent mannerIn: Haematologica / The Hematology Journal, Jg. 101, 2016, Nr. 10, S. 1216 – 1227DOI (Open Access)
-
Bone homeostasis is altered in a mouse model of myelodysplastic syndromeIn: Oncology Research and Treatment, Jg. 39, 2016, Nr. Suppl. 3, S. 123 – 123
-
Bone homeostasis is significantly altered in a myelodysplastic syndrome mouse modelIn: Haematologica / The Hematology Journal, Jg. 101 1, 2016, S. 493 – 493(Open Access)
-
Epigenetic therapy as a novel approach for GFI136N-associated murine/human AMLIn: Experimental Hematology, Jg. 44, 2016, Nr. 8, S. 713 – 726.e14DOI (Open Access)
-
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemiaIn: Leukemia, Jg. 30, 2016, Nr. 3, S. 683 – 691
-
GFI1 as a novel prognostic and therapeutic factor for AML/MDSIn: Leukemia, Jg. 30, 2016, Nr. 6, S. 1237 – 1245
-
GFI136N as a therapeutic and prognostic marker for myelodysplastic syndromeIn: Experimental Hematology, Jg. 44, 2016, Nr. 7, S. 590 – 595.e1DOI (Open Access)
-
High Frequencies of Anti-Host Reactive CD8+ T Cells Ignore Non-Hematopoietic Antigen after Bone Marrow Transplantation in a Murine ModelIn: Cellular Physiology and Biochemistry, Jg. 38, 2016, Nr. 4, S. 1343 – 1353DOI (Open Access)
-
Low GFI1 expression level drive the development of acute myeloid leukemia and fatal myeloproliferative neoplasia by blocking differentiation and P53-mediated apoptosisIn: Experimental Hematology, Jg. 44 1, 2016, Nr. 9, S. 71 – S71
-
Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1In: PLoS ONE, Jg. 11, 2016, Nr. 7, S. e0160344DOI (Open Access)
-
Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8 + T-cell priming and viral controlIn: Scientific Reports, Jg. 6, 2016, 19191DOI (Open Access)
-
72 personalized treatment approach for GFI 136N heterozygous or homozygous MDS patientsIn: Leukemia Research, Jg. 39, 2015, Nr. Suppl. 1, S. S35
-
From cytopenia to leukemia : the role of Gfi1 and Gfi1b in blood formationIn: Blood, Jg. 126, 2015, Nr. 24, S. 2561 – 2569DOI, Online Volltext (Open Access)
-
A dominant-negative GFI1B mutation in the gray platelet syndromeIn: The New England Journal of Medicine, Jg. 370, 2014, Nr. 3, S. 245 – 253DOI (Open Access)
-
Gfi1 as a novel prognostic marker and tumor suppressor in acute myeloid leukemiaIn: Onkologie, Jg. 36 7, 2013, S. 193 – 193
-
Gfi1 as a regulator of p53 and a therapeutic target for ALLIn: OncoTarget, Jg. 4, 2013, Nr. 3, S. 374 – 375
-
Gfi136N is a novel prognostic marker for the progression of myelodysplastic syndrome to Acute myeloid leukemiaIn: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 188 – 188
-
Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemiaIn: Cancer Cell, Jg. 23, 2013, Nr. 2, S. 200 – 214DOI (Open Access)
-
Hand-foot syndrome : common presentation in an uncommon situationIn: European Journal of Haematology, Jg. 91, 2013, Nr. 5, S. 472
-
Leukämien : Modellkrankheiten für die Entstehung und Behandlung von KrebsIn: Unikate: Berichte aus Forschung und Lehre, 2013, Nr. 44: Medizin : 50 Jahre Universitätsklinikum Essen, S. 114 – 125DOI, Online Volltext (Open Access)
-
Origin of the brush cell lineage in the mouse intestinal epitheliumIn: Developmental Biology, Jg. 362, 2012, Nr. 2, S. 194 – 218
-
The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in miceIn: Blood, Jg. 120, 2012, Nr. 19, S. 4006 – 4017
-
Growth factor independence 1 (Gfi1) as a regulator of lymphocyte development and activationIn: Seminars in Immunology, Jg. 23, 2011, Nr. 5, S. 368 – 378
-
Growth factor independence 1 protects hematopoietic stem cells against apoptosis but also prevents the development of a myeloproliferative-like diseaseIn: Stem Cells, Jg. 29, 2011, Nr. 2, S. 376 – 385
-
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemiaIn: Blood, Jg. 115, 2010, Nr. 12, S. 2462 – 2472
-
Evidence that Growth factor independence 1b (Gfi1b) regulates dormancy and peripheral blood mobilization of hematopoietic stem cellsIn: Blood, Jg. 116, 2010, Nr. 24, S. 5149 – 5161
-
Zinc finger protein Gfi1 controls the endotoxin-mediated Toll-like receptor inflammatory response by antagonizing NF-kappaB p65In: Molecular and Cellular Biology (MCB), Jg. 30, 2010, Nr. 16, S. 3929 – 3942
-
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemiaIn: International Journal of Hematology, Jg. 89, 2009, Nr. 4, S. 422 – 430
-
The zinc finger protein Gfi1 is implicated in the regulation of IgG2b production and the expression of Iγ2b germline transcriptsIn: European Journal of Immunology, Jg. 38, 2008, Nr. 11, S. 2916 – 3244
-
Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple MyelomaIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2025, Nr. Suppl. 1, S. 2004 – 2005DOI (Open Access)
-
Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients : A Multicenter Cohort Study
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 3383DOI (Open Access) -
Germline variant GFI1-36N affects DNA repair in AML cells resulting in sensitivity to DNA damage and repair therapy
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 135DOI (Open Access) -
Growth factor independence 1 expression regulates acute myeloid leukemia cell metabolism by regulating the equilibrium between the rate of glycolysis and oxidative phosphorylation
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 138DOI (Open Access) -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients : The Phase III GMMG-HD7 Trial
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 463 – 465DOI (Open Access) -
Leukaemia Cells Induced Metabolic Alterations in AML Associated Mesenchymal Stem Cells Via Notch Signalling
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 4347 – 4348DOI (Open Access) -
Growth factor independence 1 expression induced metabolic vulnerabilities and presents novel therapeutic opportunities in acute myeloid leukemia
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 43 – 44DOI (Open Access) -
Curcumin as a treatment approach for MDS/AML in human
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 76DOI (Open Access) -
The bone marrow niche as a potential target to improve the outcome of acute myeoloid leukemia using dexamethasone
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 73 – 74DOI (Open Access) -
Growth Factor Independent-1 (Gfi1) Is Critically Required for T-Cell Acute Lymphoblastic Leukemia (T-ALL) Tumor Initiation and MaintenanceIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 116, 2010, Nr. 21, S. 1299
-
Funktion der Transkriptonsfaktoren Gfi1 und Gfi1b in der physiologischen und malignen Entwicklung des hämatopoetischen SystemsDuisburg ; Essen, 2017
-
Affinitätschromatographie mit orientiert und nicht-orientiert immobilisiertem Calmodulin am Beispiel der Aufreinigung der Ubiquityl-Calmodulin-Synthetase Faktor 2Duisburg-Essen, 2005
-
Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
66th ASH Annual Meeting, December 7-10, 2024, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 4759 – 4760DOI (Open Access) -
Entwicklungen im Überleben beim Multiplen Myelom : eine Analyse des Krebsregisters NRW
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 85 – 86DOI (Open Access)